Takeda returns Nycomed's rights to post-op pain drug
This article was originally published in Scrip
Executive Summary
Takeda is to return the developmental and commercialisation rights to the post-operative pain relief depot product, Posidur, in Europe and other licensed territories back to US firm Durect.